VIDEO: Use of circulating tumor DNA as minimal residual disease in colorectal cancer
In this video, Arvind N. Dasari, MD, MS, discussed data from multiple ASCO Gastrointestinal Cancers Symposium presentations highlighting the use of circulating tumor DNA as a minimal residual disease in colorectal cancer.
Dasari highlighted data from the BESPOKE trial, the 80702 trial and the ALTAIR trial. The ALTAIR trial ultimately showed negative results in its question of whether adding trifluridine/tipiracil (TAS-102) would improve outcomes as compared with placebo in patients who were ctDNA or MRD-positive during surveillance.
“Overall, the study failed to meet its primary endpoint, but there was a hint of activity in stage IV patients who are MRD-positive. Although the study was negative, I must say that this is very much a successful study in demonstrating that we are able to do clinical trials in this novel space, and this opens the door for much more drug development in this space,” Dasari, an associate professor of medical oncology at The University of Texas MD Anderson Cancer Center, said.
References:
- Bando H, et al. Abstract LBA22. Presented at: ASCO Gastrointestinal Cancers Symposium; Jan. 23-25, 2025; San Francisco.
- Nowak JA, et al. Abstract 14. Presented at: ASCO Gastrointestinal Cancers Symposium; Jan. 23-25, 2025; San Francisco.
- Shah PK, et al. Abstract 15. Presented at: ASCO Gastrointestinal Cancers Symposium; Jan. 23-25, 2025; San Francisco.
Collapse
Read more about